Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma: A Case Report-Reference-Cited by-同舟云学术

Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma: A Case Report

Published:2023 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ikeda Munehiro¹,Tamada Takashi¹,Takebayashi Risa¹,Okuno Gaku¹,Yagura Iori¹,Nakamori Shohei¹,Matsumura Taishiro¹,Yoshioka Takuto¹,Kaneko Shizuka²,Kanda Naoki¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan

2. Department of Diabetes/ Endocrinology/ Metabolism, Takatsuki Red Cross Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_0860-22/_pdf

Reference30 articles.

1. 1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372: 2521-2532, 2015.

2. 2. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382: 1894-1905, 2020.

3. 3. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 4: 173-182, 2018.

4. 4. González-Rodríguez E, Rodríguez-Abreu D. Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist 21: 804-816, 2016.

5. 5. Guleria I, Gubbels Bupp M, Dada S, et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125: 16-25, 2007.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review;Experimental and Therapeutic Medicine;2024-03-12

2. Atezolizumab/lenvatinib;Reactions Weekly;2023-07-01